12.17
Drug interactions occur when another substance alters a drug's effects.
A drug–drug interaction happens when one drug alters another’s activity, reducing efficacy or increasing adverse effects.
Occasionally, interactions can be beneficial, like enhanced penicillin activity on coadministration with probenecid.
Pharmacokinetic interactions affect drug absorption, distribution, metabolism, and excretion. For example, antacids reduce tetracycline efficacy by forming unabsorbable complexes in the gut.
Pharmacodynamic interactions involve drugs acting at the same or related receptor sites, leading to additive, synergistic, or antagonistic effects.
Enzyme inhibition and induction alter drug metabolism, impacting plasma drug levels and activity. For example, ketoconazole inhibits CYP3A4, increasing toxicity risk for drugs metabolized by this enzyme.
Additionally, some drugs modify transporter activity, impacting drug absorption and elimination. For example, verapamil inhibits P-glycoprotein, potentially causing digoxin toxicity.
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced activity of penicillins when administered with probenecid. These interactions are crucial to monitor to ensure safe and effective use of medications.
Drug–drug interactions (DDIs) are a significant aspect of pharmacology that occur when the presence of one drug alters another’s effects. These interactions can significantly influence the pharmacokinetic properties of drugs, affecting their absorption, distribution, metabolism, and excretion, ultimately impacting therapeutic efficacy and safety. For example, interactions between antiretroviral drugs and other medications can complicate therapy. Ritonavir, used to inhibit HIV protease, also inhibits CYP3A4, thereby increasing the plasma levels of other drugs metabolized by this enzyme, such as certain sedatives, necessitating careful monitoring and dosage adjustments. Additionally, using antiemetic agents like aprepitant in chemotherapy can also inhibit CYP3A4, affecting the metabolism of chemotherapeutic agents, which may require dose modifications to maintain efficacy and reduce toxicity. Drug-drug interactions can involve:
Drug-drug interactions can occur via various mechanisms, such as:
Understanding and managing such interactions is crucial for maximizing therapeutic efficacy and minimizing adverse effects in clinical settings. Healthcare professionals must be vigilant about potential interactions and adjust drug regimens to ensure safe and effective patient care.
Drug interactions occur when another substance alters a drug's effects.
A drug–drug interaction happens when one drug alters another’s activity, reducing efficacy or increasing adverse effects.
Occasionally, interactions can be beneficial, like enhanced penicillin activity on coadministration with probenecid.
Pharmacokinetic interactions affect drug absorption, distribution, metabolism, and excretion. For example, antacids reduce tetracycline efficacy by forming unabsorbable complexes in the gut.
Pharmacodynamic interactions involve drugs acting at the same or related receptor sites, leading to additive, synergistic, or antagonistic effects.
Enzyme inhibition and induction alter drug metabolism, impacting plasma drug levels and activity. For example, ketoconazole inhibits CYP3A4, increasing toxicity risk for drugs metabolized by this enzyme.
Additionally, some drugs modify transporter activity, impacting drug absorption and elimination. For example, verapamil inhibits P-glycoprotein, potentially causing digoxin toxicity.
From Chapter 12:
Now Playing
Clinical Pharmacokinetics I
2.5K Views
Clinical Pharmacokinetics I
692 Views
Clinical Pharmacokinetics I
425 Views
Clinical Pharmacokinetics I
660 Views
Clinical Pharmacokinetics I
523 Views
Clinical Pharmacokinetics I
420 Views
Clinical Pharmacokinetics I
924 Views
Clinical Pharmacokinetics I
640 Views
Clinical Pharmacokinetics I
596 Views
Clinical Pharmacokinetics I
484 Views
Clinical Pharmacokinetics I
460 Views
Clinical Pharmacokinetics I
457 Views
Clinical Pharmacokinetics I
391 Views
Clinical Pharmacokinetics I
283 Views
Clinical Pharmacokinetics I
736 Views
See More